Glucagon-like peptide-1 agonism - GLP-1, common in obesity medicines - is not essential to weight management, according to preclinical research led by Richard DiMarchi and Matthias Tschöp, with funding from their startup company Bluewater Biosciences.
I think is the other way around. They extend the “I’m fullfil” hormone like from minutes to hours, so people don’t find themselves snacking an hour after eating